Learn More
AIMS To compare the once-weekly glucagon-like peptide-1 (GLP-1) receptor dulaglutide with the dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin after 104 weeks of treatment. METHODS This AWARD-5(More)
Additional safe and effective therapies for type 2 diabetes are needed, especially ones that do not cause weight gain and have a low risk of hypoglycaemia. The present study evaluated albiglutide as(More)
H yperglycemia at the time of hospital admission has been associated with shorter survival after acute myocardial infarction in patients both with and without diabetes (1–5). It is not fully(More)